Battle Card: Qpex Biopharma Sales Trigger

🚀 Battle Card: Qpex Biopharma, Inc.

• Gareth Morgan, President · 🔗 LinkedIn

• Qpex Biopharma, Inc. sales trigger signals a push for deeper anti-infective R&D and stronger public-private partnerships under new leadership. → Source

• Scaling global R&D capabilities to advance xeruborbactam into late-stage trials

• Managing complex partnerships with governments and NGOs for antibiotic access

• Primary: Portfolio Management Software → Streamline oversight across clinical and regulatory teams

• Expansion: Digital Collaboration Platform → Accelerate co-development with public-private partners

• HQ: San Diego, CA

• Employees: ≈ 80

• Rev: ≈ $25 M

• Website: qpexbio.com

🤼 Competitive Intel

• Veeva Systems — R&D Suite
• Unique edge: Integrated CTMS, eTMF, regulatory in one platform
• Evaluated by VP R&D for cross-functional visibility

• Medidata Solutions — CTMS & Data Analytics
• Unique edge: Advanced biostatistics and real-world evidence tools
• Evaluated by Head of Clinical Ops for trial acceleration

• Oracle Health Sciences — CTMS / eTMF
• Unique edge: Scalability for global registrational studies
• Evaluated by Dir. Regulatory Affairs for compliance depth

• Benchling — R&D Informatics
• Unique edge: Lab notebook + molecular data integration
• Evaluated by SVP Portfolio Mgmt for discovery workflow

✅ Do-Now Checklist for this Qpex Biopharma, Inc. sales trigger

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑<your company>❑
OFFER_BRIEF   = ❑<1-line value>❑
PROOF_METRIC  = ❑<metric>❑
CTA_STYLE     = ❑quick_call | case_study❑
TONE          = ❑friendly | punchy❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Gareth
COMPANY     = Qpex Biopharma, Inc.
DEPT        = R&D
SIZE        = ≈80
BOTTLENECK  = scaling global R&D capabilities
EVENT       = Gareth Morgan Named President
DETAIL      = your appointment as President
PAIN        = scaling global R&D capabilities to advance xeruborbactam into late-stage trials
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20251015554749&div=41152219
SIM_CO      = Shionogi
WIN_METRIC  = ≈TBD
NEXT_SIZE   = ≈150
EMP_EST     = ≈80
REV_EST     = ≈25M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈80-person R&D

Gareth—noticed your R&D team is ≈80.

That’s when scaling global R&D capabilities slows growth.

We helped Shionogi fix this with ≈ TBD.

Result: ≈TBD.  
Quick call?

PS—next bottleneck hits ≈150.

DM ≤45 words, TONE:
Saw your post about your appointment as President — scaling global R&D capabilities to advance xeruborbactam into late-stage trials.  
≈ TBD. ≈ TBD.  
Quick chat?